AnaptysBio's loss is Dermira's gain after etokimab failure
Shares in AnaptysBio (Nasdaq: ANAB) fell over 70% on Friday, after the firm announced disappointing top-line data from its ATLAS trial, a Phase IIb study of etokimab in moderate-to-severe atopic dermatitis.
Each of the dosing arms for the interleukin (IL)-33 inhibitor failed to meet the primary endpoint of the trial, a measure of improvement in eczema symptoms, relative to placebo, after 16 weeks.
The firm said it would now “postpone the initiation of its Phase IIb etokimab clinical trial in eosinophilic asthma,” while it studies the implications of the results.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze